TOKYO -- Chugai Pharmaceutical is considering unloading the production and sales rights of some 15 medications with expired patents to Taiyo Holdings for roughly 20 billion yen ($176 million), expecting generic drugs to become cheaper as Japan moves to rein in medical spending.
The medications, which include cancer treatments as well as bone and joint remedies, bring in sales of around 10 billion yen annually. Related staff are not expected to be part of the deal.
